Snakebite in Nepal: When environmental risk meets policy failure

Every monsoon, in the fertile plains of Nepal’s Terai region, as farmers work barefoot in flooded paddy fields and families sleep close to the ground in poorly sealed homes, encounters between people and snakes rise sharply. This leads to a predictable and avoidable surge in deaths related to snakebite in an area known as the country’s ricebowl. Snakebite is often treated as a medical emergency in isolation. In Nepal, it is better understood as a systemic failure at the intersection of environmental risk and health governance. These monsoon snakebite spikes are shaped by land-use patterns, housing conditions, and agricultural practices that place rural communities in close and recurring contact with venomous snakes. In addition, despite recording some of the highest snakebite mortality rates in South Asia, the country relies almost entirely on imported antivenom from India, according to Nepal’s Ministry of Health and Population. This dependence leaves rural communities exposed during the very months when risk is highest. What should be a treatable medical emergency is in fact a recurring and preventable cause of death driven not by venom alone, but by gaps in preparedness and regional health coordination. Gaps between treatment and survival Across South Asia, snakebite is recognized by the World Health Organization as one of the most neglected tropical diseases, disproportionately affecting rural and agricultural populations. Seasonal flooding, barefoot fieldwork, and limited access to health care combine to elevate risk in precisely the communities least equipped to respond. Despite its burden, snakebite has attracted little sustained development financing. Unlike other tropical diseases, it lacks strong pharmaceutical incentives, dedicated global funding mechanisms, and influential advocacy coalitions, leaving responsibility fragmented across underresourced national health systems. As a result, predictable risks affecting rural populations persist without the long-term investments required to prevent them. In Nepal, snakebite envenoming leads to an estimated 20,000 hospital admissions and around 1,000 deaths each year, based on hospital-reported data compiled by the Ministry of Health and Population and WHO. Community-based studies suggest the true burden is likely higher, particularly in rural areas where delays in seeking care and reliance on traditional healers remain common. Mortality rates in Nepal’s Terai region rank among the highest recorded in Asia, with community-based studies documenting rates substantially higher than neighboring countries. Crucially, many of these deaths occur not because treatment is unknown, but because it is unavailable when it is needed most. Antivenom is a well-established, lifesaving therapy when administered promptly. Yet patients frequently reach health posts within the critical treatment window only to find that antivenom is out of stock or entirely absent. During the monsoon of 2018, in Udayapur, the health facilities there referred over 85% of the snakebite patients due to lack of antivenom present. Similar incidence was later recorded in the Karnali province too. Clinical studies confirmed patients arrive within the treatment windows as delays of even a few hours can turn survivable bites into fatalities. The consequences extend beyond mortality. Survivors often live with long-term complications, including tissue damage, paralysis, or kidney failure, imposing lasting economic strain on households already operating at the margins of rural economies. Snakebite deaths, in this context, reflect not only clinical failures, but deeper weaknesses in how health systems anticipate and manage predictable environmental risks. The hidden costs of import dependence For decades, Nepal’s depended on antivenom produced in India. This dependence reflects both historical ties and practical constraints: Antivenom production requires specialized infrastructure, sustained public funding, and access to venom from live snake capacities. Given this, Nepal’s ability to respond to snakebite emergencies remains tightly bound to cross-border supply chains. The risks of this dependence became starkly visible in 2012, when India’s Supreme Court tightened regulations on antivenom exports, prioritizing domestic supply amid shortages at home, according to reviews cited by WHO. Although exports were not formally banned, availability to neighbouring countries became erratic. For Nepal, which lacked alternative sources or strategic reserves, the impact was immediate, with prolonged stockouts during peak snakebite seasons. Availability is only part of the challenge. WHO has warned that antivenoms produced using venoms sourced from one region may be less effective elsewhere, because venom composition can vary geographically even within the same species. In Nepal, where medically significant snakes occupy ecological niches distinct from those in India’s main production centers, this mismatch can complicate treatment outcomes and clinical decision-making. From dependence to capacity Reducing Nepal’s vulnerability to snakebite does not require new scientific breakthroughs. The technical foundations of antivenom production are well established, and several middle-income countries, including Brazil and Thailand, have shown that public-sector laboratories can produce safe and effective treatments when supported by sustained political commitment and regulatory oversight. WHO-linked analyses outlined what domestic antivenom production would require: reliable venom collection from medically significant snake species, donor animals required in the antivenom production process such as horses, skilled veterinary and laboratory personnel, and rigorous quality assurance systems. These requirements underscored that antivenom production is neither experimental nor simple, but a known public health function that demands institutional investment rather than ad hoc emergency responses. Domestic capacity also need not imply immediate self-sufficiency. Phased approaches including regional collaboration, technology transfer, and strategic stockpiling could reduce exposure to supply shocks while allowing expertise to develop over time. Nepal’s reliance on imported antivenom exposes the limits of fragmented health cooperation in South Asia. This is not a failure of medical knowledge, but of policy prioritization, financing decisions, and regional coordination that have repeatedly left known risks unaddressed. When supply chains falter or treatments fail to reflect local epidemiological realities, preventable deaths follow. Snakebite is not a mystery of medicine, but a predictable outcome of weak preparedness and uneven investment in health systems that serve rural populations.